“Empowering and equipping Europeans with health information for active personal health management and adherence to treatment”
Gravitate Health
is an integrated digital health information project
The Gravitate Health mission is to equip and empower citizens with digital information tools that make them confident, active, and responsive in their patient journey, specifically encouraging safe use of medicines for better health outcomes and quality of life.
Our vision
engagement of citizens in their own health can only be achieved with access to actionable, understandable, relevant, reliable and evidence-based information that meets their specific needs, health context, and literacy level.
Our ambition
to provide a key piece to advance this vision: the Gravitate Lens (G-Lens), which focuses (but does not conceal or filter) approved electronic product information (ePI) content, and offers a route for patients to access trustworthy, up-to-date information that better meet their individual needs.
1 – develop an integrated, digital, user-centric health information solution with two-way communication for the public so that health information from a set of trusted sources is available and understandable (such as package leaflet content) and EHR-IPS (International Patient Summary).
2 – promote adherence to treatment, safer use of medication (Pharmacovigilance), better health outcomes and quality of life through improved availability and understanding of health information from trusted sources & minimize risk through optimal use of available health information.
Gravitate Health will
- an open source digital platform supporting G-Lens functionally, demonstrated in a number of testing scenarios, and
- a White Paper with recommendations on realistic strategies to strengthen access, understanding and future use of digital services like ePIs as a tool for Risk Minimization.
Gravitate Health services and G-lens will be developed and tested within the project, using an evaluation framework to test the efficiency, efficacy, and safety of Gravitate-Health services.
Who we are
The Gravitate Health is a public – private partnership with 40 members from Europe and the US, co-led by University of Oslo (coordinator) and Pfizer (industry lead), funded by the Innovative Medicines Initiative (IMI) – a joint undertaking of the European Commission, the European Federation of Pharmaceutical Industries and Associations (EFPIA), IMI Associated Partners.
facts & figures
Project launch
Gravitate Health started at 01 November 2020
Duration
60 months
Budget
€18,5 Mio
Press Release
Read the Press Release of Nov. 16th 2020
Gravitate Health partners at a glance
About IMI
The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For further information: www.imi.europa.eu
Contact us
email: contact@gravitatehealth.eu
Prof Anne Moen
Project Coordinator
University of Oslo, Oslo, Norway
Dr Giovanna Ferrari
Project Lead
Pfizer Limited, KENT, UNITED KINGDOM
The project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945334. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations [EFPIA]. The total budget is 18.5M€ for a project duration of 60 months.
Disclaimer:
Information on this website reflects Project owner’s views and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.